Category: Health

Categories
Health

How To Get a Higher Night time’s Sleep

How To Get a Better Night's Sleep

If you don’t commute to work, it can be easy to spend your entire mornings inside. But exposure to sunlight serves an important purpose: It shuts down the release of melatonin, a hormone that promotes sleep. “Most brain fog in the morning is caused by continued melatonin production,” said Michael Breus, a clinical psychologist and the author of “The Power of When.” “When sunlight hits your eye, it sends a signal to your brain to tell the melatonin faucet to turn off.” Aim to get at least 15 minutes of sunlight first thing every morning.

Working from home — sometimes from our beds — has erased a lot of the boundaries between work and sleep. But turning your mattress into an office can condition your brain to view your bed as a place that makes you stressed and alert, which can lead to insomnia. That’s why sleep experts say you have to reserve your bed for two activities only. “The bed is for sleeping or sex,” said Dr. Rosen. “If you’re not doing either of those things, then get out of bed. If you have the luxury of going to a different room, then that’s even better. You have to break the association of being awake in bed.”

The pandemic led people to cut back on physical activity. But exercise is the easiest way to improve sleep, said Dr. Breus. “Sleep is recovery,” he added. “If you don’t have anything to recover from, your sleep isn’t going to be that great.” At least 29 studies have found that daily exercise, regardless of the type or intensity, helps people fall asleep faster and stay asleep longer, especially among people who are middle-aged or older. According to the Sleep Foundation, people with chronic insomnia can fall asleep about 13 minutes faster and gain up to 20 extra minutes of sleep per night by starting an exercise routine. One caveat: End your exercise at least four hours before bedtime, otherwise it could interfere with your sleep by raising your core body temperature, said Dr. Breus.

Caffeine has a half-life of six to eight hours and a quarter-life of about 12 hours. That means that if you drink coffee at 4 p.m., “you’ll still have a quarter of the caffeine floating around in your brain at 4 a.m.,” said Dr. Breus. Avoiding caffeine in the evening is a no-brainer. But ideally you should steer clear of caffeine after 2 p.m. so your body has enough time to metabolize and clear most of it from your system.

If you drink alcohol, limit yourself to two drinks in the evening and stop at least three hours before bed. Alternate each drink with a glass of water. Because alcohol is a sedative, some people drink a nightcap to help them fall asleep faster. But alcohol suppresses REM sleep and causes sleep disruptions, which will worsen the overall quality of your sleep. “The closer you drink to your bedtime, the worse your sleep is going to be,” said Dr. Breus.

Advice From Wirecutter on How to Sleep Better

Wirecutter’s “Five Days to Better Sleep” Challenge

Wide Awake at 3 a.m.? Don’t Look at Your Phone

5 Ways to Beat Coronavirus Anxiety so You Can Sleep

I Tried a Virtual Bedside Sleep Coach for a Week. It Was Weird, and Weirdly Effective.

The occasional bout of insomnia is nothing to fret about. But if you make changes to your sleep routine and nothing seems to help, then it might be time to see a doctor. A sleep specialist can determine whether you need cognitive behavioral therapy, medication or another treatment. Or it could be the case that you have an underlying sleep disorder, such as restless legs syndrome or sleep apnea. A doctor would evaluate you to find out.

If you need help, go to the American Academy of Sleep Medicine’s website, sleepeducation.org, and enter your ZIP code to find a local sleep doctor or provider. “Don’t suffer in silence,” said Dr. Abbasi-Feinberg. “Ask for help if you need it. There are sleep physicians everywhere, and that’s what we’re here for.”

Categories
Health

Florida, Alabama not reporting every day Covid case and dying information

Florida, Alabama no longer reporting daily Covid case and death data

Florida and Alabama will no longer report daily Covid cases and deaths as vaccinations rise and states begin moving into the “next phase” of the pandemic.

Florida rolled out a weekly Covid data reporting plan on Friday, the state emergency management department said on its website.

“Florida is moving into the next phase of the COVID-19 response,” the Florida Department of Health wrote in a statement emailed Monday. “As vaccinations go up and the positivity rate of new cases declines, the Florida Department of Health has put in place a weekly reporting schedule.”

Alabama introduced a new schedule on Monday in which the state updates case and death dates three times a week and vaccination dates twice a week.

“In addition to decreasing COVID-19 cases, hospitalizations and deaths, the Alabama Department of Public Health (ADPH) will update its dashboard less frequently,” wrote Dr. Karen Landers, an Alabama health officer, in a news release on Friday.

The changes signal a shift in attitudes towards the pandemic, as the U.S. averaged around 16,000 new infections per day over the past week, a low number that has not been seen since the early days of the outbreak.

Florida reported an average of eight new cases per 100,000 residents last week and Alabama reported about 8.5 cases, well below their pandemic highs of 84 and 87 per 100,000, respectively, according to Johns Hopkins University.

Still, public health experts warn that relaxing data reporting guidelines could be risky as the nature of the outbreak has changed rapidly in various places over the past year.

“I think we have to learn from this pandemic that you can’t just imagine that there will be no change,” said Dr. Wafaa El-Sadr, professor of epidemiology and medicine at Columbia University, noted that infection rates were high in her hometown of New York were low last summer before skyrocketing again in winter.

“If you start to see a trend, even after a week, you can fly a red flag and be vigilant,” she added. “I think it’s a little premature to let our vigilance down.”

Of course, the last great wave of Covid infections in the US started over the winter before vaccines were available. In Alabama, however, only 36% of residents have had at least one injection, one of the lowest rates in the country, data from the Centers for Disease Control and Prevention shows. At 50%, the numbers in Florida are closer to the statewide rate of 52% of the population who are at least partially vaccinated, but still lagging behind.

Dr. Joseph Kanter, the chief medical officer in Louisiana, said his state started reporting Covid data five days a week about a month ago but has no plans to make any changes beyond that.

“I think the daily updates, at least Monday through Friday, are still relevant and helpful in informing the public,” he said.

“We’re still a long way from the woods,” added Kanter, despite encouraging trends in cases, hospitalizations and death rates. “We’re really fine, but the general feeling is that the health department is still out of the woods and I’m aware that I’m sending the wrong idea.”

Reporting on Covid data can be resource-intensive, and many state governments have struggled to build or upgrade technology systems that could handle the unprecedented demands last spring. The data is also “maintenance-intensive,” according to Kanter, who stated that his department, for example, needs to deduplicate multiple positive tests for a person in a recorded case in order to keep accurate records.

“It’s a long time, a big manpower investment, but we are still in a public health emergency,” he said.

Many states have ditched daily reporting over the course of the pandemic, with nearly 20 reporting dates five days a week, according to a list maintained by Johns Hopkins. However, Florida is the only state that currently reports both case and death data once a week, and according to Johns Hopkins, only Kansas and Alabama report three days a week.

The Alabama Department of Health was unable to be reached for comment.

Categories
Health

Within the U.S., vaccines for the youngest are anticipated this fall.

In the U.S., vaccines for the youngest are expected this fall.

Coronavirus vaccines could be available to U.S. children 6 months and older this fall, drug makers say. Pfizer and Moderna are testing their vaccines on children under the age of 12 and are expected to have results for children ages 5 to 11 by September.

Compared to adults, children are significantly less likely to develop serious illnesses after being infected with the coronavirus. However, according to the American Academy of Pediatrics, nearly four million children in the United States have tested positive for the virus since the pandemic began.

Doctors continue to see rare cases of multisystem inflammatory syndrome in children, a disease related to Covid-19 that can affect multiple organs, including the heart. Vaccinating children should further help contain the virus by reducing its spread in communities.

Pfizer announced Tuesday that it would test its vaccine on children ages 5 to 12. It will begin testing the vaccine in infants as young as six months in the next few weeks.

The company hopes to apply to the Food and Drug Administration for emergency approval of the vaccine for children ages 5-11 in September. Kit Longley, a spokesman for Pfizer, could soon have results for children ages 2-5.

Data from the study for children between 6 months and 2 years old could arrive in October or November, followed by a possible filing with the FDA soon after, Longley added.

The Pfizer BioNTech vaccine was approved for use in children between the ages of 12 and 15 last month.

Based on data from a previous safety assessment study, Pfizer will give two doses of 10 micrograms each – one third of the dose given to adolescents and adults – in children aged 5 to 11 years and children aged 6. two doses of three micrograms each give months to 5 years.

“We are taking a conscious and careful approach to understanding the safety and tolerability of the vaccine in younger children,” said Dr. Bill Gruber, Senior Vice President at Pfizer.

The study will enroll up to 4,500 children at more than 90 clinical centers in the United States, Finland, Poland and Spain. Pfizer researchers plan to submit full data from the studies for publication in a peer-reviewed journal this summer.

In March, Moderna began testing different doses of its vaccine in younger children. This study aimed to enroll 6,750 healthy children in the United States and Canada. Results are not expected before the end of summer, and the vaccine will take longer to get approved by the FDA.

“I think it will be early autumn just because we have to age very slowly and carefully,” said Moderna boss Stéphane Bancel on Monday.

The company announced late last month that its vaccine was highly effective in 12-17 year olds and plans to apply to the FDA for approval in that age group. Last week, Moderna also asked the agency for full approval of its vaccine rather than the emergency use it is currently approved for.

The US won’t be the first country in the world to approve a coronavirus vaccine for young children. China has approved Sinovac’s vaccine for children aged 3 and over, the company’s chairman said. The approval was not officially announced.

Categories
Health

U.S. should vaccinate extra individuals earlier than Delta turns into dominant Covid variant

U.S. must vaccinate more people before Delta becomes dominant Covid variant

Dr. Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases, testifies during a Senate Committee on Health, Education, Labor and Pensions hearing about the federal response to the coronavirus on Capitol Hill March 18, 2021 in Washington, DC.

Susan Walsh | Swimming pool | Getty Images

U.S. health officials are making efforts to get more Americans vaccinated to prevent the Delta variant, first identified in India, from spreading to the United States.

The variant has become the dominant variety in the UK, accounting for an estimated 60% of new cases. It’s now more common than the Alpha strain, formerly known as the B.1.1.7 strain and first identified in the UK, and transmission peaks in people between the ages of 12 and 20, said Dr. Anthony Fauci., White House chief medical officer, said at a news conference Tuesday.

In the US, the delta variant makes up more than 6% of the cases that scientists have been able to sequence, he said. The real number is likely higher since the US does the genetic sequence on a fraction of the time.

“In the UK, the Delta variant is quickly becoming the dominant variant … It replaces the B.1.1.7,” said Fauci. “We cannot allow that in the USA.”

President Joe Biden’s goal is to have at least one vaccination of 70% of all US adults by July 4th. It’s a bit of a chore, less than four weeks before it starts and 63.7% of the adult population got their first vaccination, according to data compiled by the Centers for Disease Control and Prevention. About 53% of all adults in the United States are fully vaccinated, according to the CDC.

First discovered in October, the Delta variant has spread to at least 62 countries, the World Health Organization announced last week.

“We continue to see significantly increased transmissibility and a growing number of countries reporting outbreaks associated with this variant,” the WHO said last week of the Delta strain, noting that further studies were a high priority.

The Delta Tribe has India in a stranglehold, causing a surge in infections and deaths that has clogged hospital systems. The Indian government announced Monday that the country will shortly begin making Covid-19 vaccines available to all adults in the country free of charge.

Fauci also said the Delta variant is more contagious and could be associated with a higher risk of hospitalization than the original “wild-type” Covid-19 strain.

Studies also show that two doses of the Pfizer or AstraZeneca shots are effective against the Delta strain, according to the National Institutes of Health.

According to NIH data, two doses of the Pfizer vaccine were found to be 88% effective against the Delta variant, while two doses of the AstraZeneca shot were 60% effective against the strain.

Fauci emphasized the importance of receiving two doses after NIH studies showed that three weeks after administration, just one dose of either vaccine provided only 33% effectiveness against the Delta variant.

Categories
Health

A U.N. Declaration on Ending AIDS Ought to Have Been Simple. It Wasn’t.

A U.N. Declaration on Ending AIDS Should Have Been Easy. It Wasn’t.

The United Nations on Tuesday adopted new targets for ending AIDS as a public health threat by 2030, a target that most countries could seemingly easily agree to. But consensus was elusive.

In early negotiations on what is known as the Political Declaration, the United States and the European Union fought to outlaw policies and laws that stigmatize or even criminalize high-risk groups – and drastically scaled back measures to relax patent protection for HIV drugs .

The UN Declaration sets priorities for the global fight against AIDS and guides national policy. There are also opportunities for global health groups and civil society organizations to put pressure on governments to honor their commitments.

After several days of intensive work by delegates from some countries and skilful negotiations by others, the member countries adopted a final version of the declaration on Tuesday morning. The final draft includes an important new goal of having most nations reform discriminatory laws so that less than 10 percent of the world’s countries would take action that unfairly targets people at risk of or living with HIV

“These laws drive the most severely affected by HIV away from HIV prevention and treatment,” said Matthew Kavanagh, director of the Global Health Policy and Politics Initiative at Georgetown University. “This could be a vital tool to get the world back on track to end AIDS.”

On Monday, Dr. Kavanagh and colleagues have a new piece of work showing that countries that criminalize same-sex relationships, drug use, and sex work have had far less success in fighting HIV

But the declaration does not move the needle to patent protection. The United States was among the nations whose delegates significantly watered down or shortened the language to relax patents to provide better access to affordable HIV medicines in low and middle income countries, an attitude endorsed by the Biden government directly contradicted patent waiver for Covid vaccines.

“The mixed messages from the government in the face of recent support for the waiver of Covid-19 vaccine patents are confusing and disappointing,” said Annette Gaudino, director of policy at the Treatment Action Group, an advocacy group in New York. “This would by far not be the first time the US has put drug company profits above people and public health.”

The UN brings together heads of state, health ministers and non-governmental organizations to set priorities for the fight against the HIV pandemic every five years. At a similar meeting in 2016, member countries agreed to aim for less than 500,000 new HIV infections per year, less than 500,000 AIDS-related deaths and the eradication of HIV-related discrimination by 2020.

The world did not achieve these goals: in 2020 around 1.5 million people became infected with HIV and around 690,000 died.

Ending AIDS by 2030 was an ambitious goal adopted by the UN in 2015 as part of a broader agenda for sustainable development. But without more advanced policies and laws, the goal is not achievable, said Dr. Kavanagh.

“To end AIDS by 2030, governments must commit to taking a people-centered, rights-based approach to HIV, working on policy and legal reform, engaging and supporting communities, and ending inequalities,” said Winnie Byanyima, Executive Director from executive UNAIDS said in an email statement.

The original draft of the April 28 statement included a commitment to end “criminal laws, policies and practices, stigma and discrimination based on HIV status, sexual orientation and gender identity.”

Delegates from a few countries, including the Africa Group, China, Russia and Iran, tried to erase allusions to sexual or gender identity or to sex education for girls. This has only partially succeeded: the current text calls for prevention approaches that are tailored to risk groups, including sex workers, men who have sex with men, drug users and transgender people.

Delegates from African countries have successfully inserted a language in which they reaffirm “the sovereign rights of member states” and emphasize that the commitments in the declaration would be implemented “in accordance with national laws, national development priorities and international human rights”. About half of the countries where homosexuality is illegal are in Africa.

The declaration in its current form also calls on countries to “empower women and girls to take care of their sexual and reproductive health and reproductive rights,” a section that Saudi Arabia, Russia and the Holy See attempted remove the text.

Representatives from Belarus, China and Russia also deleted a section calling on member countries to recognize citizens’ autonomy in matters of sexuality; its replaced text encouraged “responsible sexual behavior, including abstinence and fidelity”. The final document has been reverted to the original text.

Including language through high-risk groups is critical to success, some experts said. Gays and other men who have sex with men, people who inject drugs, and female sex workers are almost 30 times more likely to have HIV than the general population.

If these groups don’t have access to preventive therapy, clean needles, condoms, or education, “we will undermine the possibility of actually ending AIDS by 2030,” said Eric Sawyer, an advocate for people living with HIV and long-term survivors.

An early draft of the declaration also contained a longer section aimed at relaxing patent protection. Under the current global rules, only the 50 least developed countries are allowed to delete patents on pharmaceutical products in order to distribute them to citizens.

The draft called for “an indefinite moratorium on international intellectual property regulations for drugs, diagnostics and other health technologies”. Representatives from the United States and Switzerland deleted this section. A representative from the European Union said: “This is not the place to discuss these general issues.”

The United States also added language to the reduced version to recognize the “importance of the intellectual property rights regime in contributing to a more effective AIDS response.”

Activists said an anti-patent waiver stance was perfectly consistent for the European Union, which also spoke out against waiving patents on Covid vaccines. Vaccine manufacturers have argued that patent protection is essential to fuel innovation.

Citing the urgent need for vaccines, however, Biden government officials have said they would support a patent waiver that would allow companies to manufacture cheaper versions of the vaccines for the rest of the world.

Given this trend, “it would be really inconsistent” for the US to oppose a relaxation of patent protection for HIV drugs, said Brook Baker, law professor at Northeastern University and senior policy analyst with the Health Global Access Project, an advocacy group.

“Why in the world should the US be talking on a seemingly almost identical subject from two sides of the mouth?”

Categories
Health

Biogen faces robust questions on $56Okay-a-year worth of latest Alzheimer’s drug

Biogen faces tough questions on $56K-a-year price of new Alzheimer's drug

A person skates past Biogen Inc. headquarters in Cambridge, Massachusetts on Monday, June 7, 2021.

Adam Glanzman | Bloomberg | Getty Images

Biogen faced tough questions from Wall Street analysts Tuesday about the annual cost of $ 56,000 for its newly approved Alzheimer’s drug Aduhelm – a price that executives call “fair” and “responsible”.

Biogen’s shares rose 38% Monday after the FDA announced it had approved the company’s drug scientifically known as aducanumab. It’s the first drug approved by U.S. regulators to slow cognitive decline in people with Alzheimer’s, and the first new drug for the disease in nearly two decades.

The biotech company said it is charging $ 56,000 for an annual course of the new treatment, more than the $ 10,000-25,000 price some Wall Street analysts expected. This is the wholesale price, and the cost that patients actually pay depends on their health insurance plan.

Some analysts and stakeholders immediately questioned how the company could justify the price – about five times higher than expected – especially as medical experts continue to debate whether there is enough evidence that the drug actually works and the industry has been criticized for drug prices .

The FDA departed from the advice of its independent panel of external experts, which unexpectedly declined to approve the drug last fall, citing inconclusive data.

“Our only concern here is the annual cost of aducanumab and whether the sticker shock at $ 56,000 a year (we were at $ 10,000) could further stimulate drug price reviews,” Stifel analyst Jeff Preis told investors Monday in a note.

On a call to investors Tuesday morning, Evercore ISI analyst Umer Raffat congratulated the Massachusetts-based company on US approval of the drug before asking executives to explain the price.

“I think there is a discrepancy between some of the words you shared in your press releases like responsibility, access, health equity, and price, especially given the basic care population,” he told executives.

JP Morgan analyst Cory Kasimov later asked executives how much the state health insurance program Medicare is likely to pay for the drug and how concerned executives are about the “backlash” the industry will face on pricing.

Biogen executives said the overall price of the new treatment is “underpinned” by the value it is expected to bring to patients, caregivers and society. They insisted that the price was “responsible” and stated that the disease costs the US billions each year.

The Alzheimer’s Association estimates that more than 6 million Americans are living with the disease. The company said it currently has the capacity to deliver the drug to 1 million patients annually, with more than 900 locations in the U.S. poised to launch the new drug.

“We want to ensure that Aduhelm is affordable for patients and sustainable for health systems,” said one executive.

The company has pledged not to increase the price of the new drug over the next four years. However, executives said they were “open-minded” and suggested reconsidering the price as the company assesses demand over the next few years.

Michel Vounatsos, CEO of Biogen, joined CNBC on Monday and said the drug’s price will allow the company to continue investing in its pipeline of drugs for other diseases. He added that the company works closely with Medicare as well as private insurers.

Categories
Health

Alzheimer’s Drug Is Bonanza for Biogen, Most Seemingly at Taxpayer Expense

Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense

In addition to the United States, Biogen has asked regulators in Australia, Brazil, Canada, the European Union, Japan and Switzerland to review the drug.

The U.S. approval is a crucial victory for a company that has been counting on Aduhelm to make up for stalled or declining revenue from its other products. Competitors last year introduced generic versions of Biogen’s multiple sclerosis drug, Tecfidera, causing the company to miss out on hundreds of millions of dollars in revenue from what had been its top-selling product.

The approval “completely transforms” Biogen, said Brian Skorney, an analyst at Robert W. Baird & Company, who is projecting that the drug will generate $7.5 billion in revenue in 2025. “This changes it from a declining revenue company to a growth company,” he said, and, in so doing, “opens up a bit of Pandora’s box” in terms of pricing and reimbursement.

While only patients with mild cognitive decline were enrolled in the clinical trials, the F.D.A. approved the drug for anyone with Alzheimer’s, a much broader group of patients than many experts were expecting.

Just how lucrative the drug will be for Biogen will depend on how many patients it can reach — and in what circumstances, and for how long, insurers are willing to pay for it.

Dr. Steve Miller, the chief clinical officer at the insurer Cigna, said on Monday that he expected his company and most of its peers would pay for the drug only for patients with mild cognitive symptoms and higher-than-normal levels of the protein amyloid in their brains.

“There’s just no data that more advanced patients will benefit,” he said.

Dr. Miller said he was disappointed that the F.D.A. had made so many patients eligible. “You’re leaving the tough decision-making about who should be covered to the individual payers,” he said.

Categories
Health

Vaccine journey offers? Russia plans packages to revive tourism business

Vaccine travel deals? Russia plans packages to revive tourism industry

Tourists walk along Red Square in front of St. Basil’s Cathedral in Moscow on November 6, 2020.

ALEXANDER NEMENOV | AFP | Getty Images

With Russia’s coronavirus shot Sputnik V sluggishly received among its own citizens, Russia is considering launching travel packages for Covid vaccinations for tourists.

Russian state news agency Tass quoted one of the country’s tourism industry leaders as saying that “vaccination prices” were ready, but that visas and entry requirements for foreign visitors were holding them back.

“The product is ready, but the issues of visa support and legal entry for foreigners who want to get the Russian vaccine have yet to be resolved,” Andrei Ignatyev, president of the Russian Union of Travel Industry (RUTI), told Tass.

The price of a three-week vaccination rate for foreigners will be anywhere from $ 1,500 to $ 2,500, excluding the airline’s expense, Ignatyev added.

Vaccine prices seem to have the blessing of Russian President Vladimir Putin. Speaking at the International Economic Forum (SPIEF) in St. Petersburg last week, Putin asked the government to examine the possibility of offering paid Covid vaccinations to foreign visitors to Russia.

Russia is keen to revitalize its tourism industry to end the Covid pandemic. Like other countries around the world, last March Russia introduced entry restrictions for almost all foreigners (with the exception of some workers), bringing tourism to a standstill. Since then, entry restrictions have been relaxed if visitors present negative Covid tests before traveling.

Immunization tourism could prove popular for people in countries struggling to get their own immunization programs off the ground. The Times of India reported last month that a Delhi-based travel agent was offering a 24-day package tour to Russia that included two shots of the Sputnik-V vaccine and a 21-day interval to allow sightseeing between vaccinations.

Slow domestic recording

Russia was the first country in the world to approve a coronavirus vaccine – its own Sputnik V – last August, but despite its rapid approval and rollout, domestic uptake of vaccination has been sluggish.

According to data compiled by Our World In Data, only 9% of the adult population are fully vaccinated so far, placing Russia behind Brazil, India, Turkey and Mexico in terms of vaccination progress.

Target market

In Europe, according to Our World In Data, over 23% of adults are now fully vaccinated. Russia will therefore look for potential vaccination tourists in the distance, said Ignatiev.

“The countries of Africa and Latin America have shown great interest in such a tourist product throughout the vaccination campaign in Russia, and RUTI has received such inquiries,” he added, according to Tass.

In late May, President Putin announced Russia would not make Covid vaccines compulsory for its citizens and said people should recognize the need to vaccinate for themselves. He also stressed that the vaccine was safe; According to peer-reviewed results from its late-stage clinical study published in February in the medical journal The Lancet, Sputnik V was found to be 91.6% effective in preventing the development of Covid-19.

“I would like to emphasize again and appeal to all of our citizens: think carefully, remember that the Russian vaccine – practice has already shown that millions (of people) have used it – is currently the most reliable and safest. ” “Said Putin. “In our country, all the conditions for a vaccination are in place.”

A poll published in March by the Russian electoral center Levada found that 62% of people did not want to receive the vaccine, with the greatest reluctance noted among 18-24 year olds.

Categories
Health

Biogen CEO says $56,000 yearly for Alzheimer’s drug is ‘honest,’ guarantees to not hike value for at the very least four years

Biogen CEO says $56,000 annually for Alzheimer’s drug is 'fair,' promises not to hike price for at least 4 years

Michel Vounatsos, CEO of Biogen, told CNBC Monday that the list price of $ 56,000 per year for the company’s FDA-approved Alzheimer’s drug aducanumab was “fair”.

However, the Massachusetts-based biotech has vowed not to increase the price of the drug, which it marketed under the Aduhelm name, for the next four years, Vounatsos said.

The price of the drug reflects “two decades without innovation” and will also allow Biogen to continue investing in its pipeline of drugs for other diseases, he said in an interview with CNBC’s “Power Lunch”. He added that the company works closely with the federal health insurance program Medicare, as well as with private insurers.

Biogen’s shares rose up to 60% on Monday after the Food and Drug Administration announced it approved the company’s drug for the disease. It’s the first drug approved by U.S. regulators to slow cognitive decline in people with Alzheimer’s, and the first new drug for the disease in nearly two decades.

Alzheimer’s disease is a progressive neurodegenerative disease that slowly destroys memory and thinking skills. The Alzheimer’s Association estimates that more than 6 million Americans live with it. According to the group, this number is expected to rise to almost 13 million by 2050.

The FDA’s decision was eagerly awaited. The drug is also expected to generate billions in revenue for the company offers new hope to friends and families of patients living with the disease.

Biogen said Monday that aducanumab’s list price is $ 56,000 a year, which was higher than the $ 10,000-25,000 price some analysts had expected. The expenses for the patient depend on their health insurance.

When asked if the company expects patient pressures on price to drop, Vounatsos found that the disease and other forms of dementia cost the US over $ 600 billion annually and patients $ 500,000 annually.

It is time to “invest” in treatment, he added.

Categories
Health

Learn how to Rearrange Your Submit-Pandemic ‘Friendscape’

How to Rearrange Your Post-Pandemic ‘Friendscape’

It requires daily or weekly attention to maintain foreground friends, so there are necessarily a limited number of slots (four to a maximum of six). Some of these can be filled in by your romantic partner, parent, sibling, or child. Since they are in the foreground, foreground friends are the ones who have the greatest impact on your health and wellbeing, for better or for worse.

What are the hallmarks of good foreground friends? First and foremost, they make you feel better about the world and about yourself. They are there for you, listen to you, and while they don’t always agree with you, they get you. There is a sense of reciprocity and reciprocity in terms of help and commitment. And most of all, you basically enjoy being with them, just as they enjoy being with you.

People who don’t belong in your foreground are the ones who don’t seem really pleased when something good happens to you and show a touch of glee when something goes wrong. Another clue is that they are boastful, self-righteous, error-prone, or mischievous in conversation – or keep bringing the conversation back to themselves. And stay away from anyone who is not defending you, when someone else is slandering you or worse, intruding on you.

Susan Heitler, psychologist and author of The Power of Two, which examines friendship in the context of marriage, cautioned that you should also look to yourself when making decisions about who to populate your post-pandemic world: ” Maybe it’s you, not necessarily the other person, who makes the relationship “asymmetrical” and unsatisfactory.

You cannot have good friends if you are not a good friend yourself. Do you only report when you want something or have nothing better to do? Are you the one who is argumentative or always talking about yourself? Do you say or do things to lessen your friend’s joy? Are you too demanding? Prejudicial? Emotionally unavailable?

Of course, nobody is always a perfect friend. We all have our less-than-admirable moments. But a solid and good friendship is one in which the two of you are able to handle willful and unintentional offenses.

“It’s not the lack of conflict that determines the success of a relationship,” says Mahzad Hojjat, a professor of psychology who studies friendship at the University of Massachusetts at Dartmouth. “This is how the conflict is resolved.”